Combination Therapy of High-Dose Rabeprazole Plus Metronomic Capecitabine in Advanced Gastro-Intestinal Cancer: A Randomized Phase II Trial

SIMPLE SUMMARY: This is the first phase II study of high dose rabeprazole repurposing (1.5 mg/kg bid, three days a week) combined with metronomic capecitabine (mCAP), 1500 mg/daily, in gastrointestinal cancer, aimed at evaluating the activity and safety of high-dose proton pump inhibitor in combinat...

Descripción completa

Detalles Bibliográficos
Autores principales: Roberto, Michela, Romiti, Adriana, Mazzuca, Federica, Milano, Annalisa, D’Antonio, Chiara, Lionetto, Luana, Falcone, Rosa, Strigari, Lidia, Simmaco, Maurizio, Fais, Stefano, Marchetti, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7690608/
https://www.ncbi.nlm.nih.gov/pubmed/33105819
http://dx.doi.org/10.3390/cancers12113084

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7690608/
https://www.ncbi.nlm.nih.gov/pubmed/33105819
http://dx.doi.org/10.3390/cancers12113084

Ejemplares similares